2024-11-01 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report 

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods company.

**1. Performance Comparison:**

* **JNJ Cumulative Return:** 33.41%
* **S&P 500 (VOO) Cumulative Return:** 131.38%
* **Difference:** -97.97%
* **Relative Divergence:** 6.5% (This means JNJ's performance is currently in the 6.5th percentile of its historical performance range relative to S&P 500.)

**2. Recent Price Movement:**

* **Closing Price:** 159.86 (Last-market: 159.81)
* **5-day Moving Average:** 160.61
* **20-day Moving Average:** 162.03
* **60-day Moving Average:** 162.72

**3. Technical Indicators:**

* **RSI:** 45.42 (Neutral: RSI values between 30 and 70 suggest that the stock is neither overbought nor oversold.)
* **PPO:** -0.22 (Negative: A negative PPO value suggests that the stock price is declining relative to its moving averages. )
* **Delta_Previous_Relative_Divergence:** -0.76 (Negative: Indicates a short-term downward trend in relative divergence. 
* **Expected Return:** 0.0% (This signifies that JNJ is projected to have similar long-term performance to the S&P 500, assuming a 2-year+ investment horizon.) 

**4. Recent Earnings Performance:**

| Date       | EPS     | Revenue     |
|------------|---------|-------------|
| 2024-10-23 | 1.12    | 22.47 B$   |
| 2024-07-25 | 1.95    | 22.45 B$   |
| 2024-05-01 | 1.35    | 21.38 B$   |
| 2024-02-16 | 1.68    | 21.39 B$   |
| 2023-10-27 | 10.32   | 21.35 B$   |

**Analysis:** The most recent earnings report (2024-10-23) showed an EPS of 1.12 and revenue of 22.47B$. This result is pending analyst expectations for the period. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter     | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2024-09-30 | $22.47B  | 69.01%       |
| 2024-06-30 | $22.45B  | 69.40%       |
| 2024-03-31 | $21.38B  | 69.55%       |
| 2023-12-31 | $21.39B  | 68.23%       |
| 2023-09-30 | $21.35B  | 69.06%       |

**2) Capital and Profitability:**

| Quarter     | Equity    | ROE    |
|------------|-----------|--------|
| 2024-09-30 | $70.16B  | 3.84%  |
| 2024-06-30 | $71.54B  | 6.55%  |
| 2024-03-31 | $70.02B  | 4.65%  |
| 2023-12-31 | $68.77B  | 5.89%  |
| 2023-09-30 | $71.23B  | 36.54% |

**Analysis:** Johnson & Johnson consistently demonstrates strong profitability with high profit margins. This suggests a robust business model and efficient cost management. ROE is also stable and fluctuating around the average, indicating the company's effectiveness in generating profits from its shareholder equity.

**6. News and Recent Events:**

* **Recent Earnings News:**  You will need to specify the date range for this analysis, as the report requests information within the last 2 days. 
* **Recent Market Outlook:** You will need to specify the source of this information, as it requires information on the stock's current market outlook and analysts' opinions. 
* **Analyst Opinions and Performance Highlights:**  Provide information on recent analyst ratings and performance highlights. This information can be found from sources like FINBOLD and other reputable financial data platforms. 

**7. Comprehensive Analysis:**

Based on the analysis above, Johnson & Johnson (JNJ) presents a mixed outlook. The company's strong financial performance with high profit margins and stable ROE signals a financially sound and well-managed entity. However, the stock's recent performance has been lagging behind the S&P 500, and the technical indicators suggest a short-term downward trend. The expected return of 0.0% suggests that JNJ's long-term potential might be similar to the broader market. Further analysis of the company's recent news and analyst opinions will provide a more comprehensive understanding of the stock's current and future prospects. 
